首页 | 本学科首页   官方微博 | 高级检索  
     


Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children
Authors:Claudio Carnevale,Luis Ferr  n‐De la Cierva,Guillermo Til‐P  rez,Jos   Antonio Pe  a‐Zarza,Borja Osona‐Rodriguez,Joaquina Martinez‐Lozano,Pedro Sarrí  a‐Echegaray,Diego Arancibia‐Tagle,Manuel Tom  s‐Barber  n
Affiliation:Claudio Carnevale,Luis Ferrán‐De la Cierva,Guillermo Til‐Pérez,José Antonio Peña‐Zarza,Borja Osona‐Rodriguez,Joaquina Martinez‐Lozano,Pedro Sarría‐Echegaray,Diego Arancibia‐Tagle,Manuel Tomás‐Barberán
Abstract:
Recurrent respiratory papillomatosis can be a devastating condition for a child, with severe consequences. Currently, there is no proven successful medical treatment. We describe the use of systemic bevacizumab to treat two children affected by aggressive recurrent respiratory papillomatosis. Respiratory symptoms and quality of life improved dramatically in both patients, without observing any toxicity. The only complication was mild proteinuria. Systemic bevacizumab is a promising adjuvant treatment in aggressive recurrent respiratory papillomatosis in children. It is effective and well tolerated. Further studies are needed to establish the optimal dosing frequency and duration of therapy. Laryngoscope, 129:1001–1004, 2019
Keywords:Respiratory papillomatosis  laryngeal papillomatosis
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号